<h4>Background</h4>The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D) and cardiovascular risk. Here, FGF23 is linked to type 2 diabetes mellitus.